We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the most boring stocks. TheFly reported on March 12 that Wedbush raised its price target on DNTH to $103 from $80 while reiterating an Outperform rating. The firm updated its estimates following the company’s recent secondary offering, factoring in the $675 million capital raise and assuming full exercise of the overallotment option. While awaiting more detailed CAPTIVATE data, Wedbu ...

5AM Venture Management disclosed a full exit from Dianthus Therapeutics (NASDAQ:DNTH) on February 17, 2026, selling 365,053 shares worth $14.36 million in the fourth quarter. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, 5AM Venture Management sold its entire stake of 365,053 shares in Dianthus Therapeutics. The quarter-end value of the position decreased by $14.36 million as a result of the exit. What else to know Top holdings after the filing: ...

Core Viewpoint - Dianthus Therapeutics, Inc. has successfully completed a public offering of 8,470,989 shares of common stock, raising approximately $719 million to support its clinical and preclinical development activities, as well as general corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $81.00 per share, with underwriters exercising an option to purchase an additional 1,157,407 shares [1]. - Pre-funded warrants were also offered, allowing certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering was conducted under a shelf registration statement that was declared effective on January 30, 2026, and included a related registration statement filed on March 10, 2026 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the company's clinical and preclinical development activities, enhance commercial readiness, and for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 7,313,582 shares of common stock at $81.00 per share, aiming to raise approximately $625 million before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering is expected to close on March 12, 2026, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,157,407 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on January 30, 2026 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3]. Group 4: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].

Core Insights - The article highlights the offerings of Biotech Analysis Central, a service focused on in-depth analysis of pharmaceutical companies, providing valuable insights for investors in the biotech sector [1][2]. Group 1: Company Overview - Biotech Analysis Central is led by Terry Chrisomalis, who has extensive experience in the biotech sector and aims to generate long-term value from healthcare investments [2]. - The service includes a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, each with detailed analysis [2]. Group 2: Subscription Details - A two-week free trial is currently available for new subscribers, with a monthly subscription priced at $49 [1]. - An annual subscription offers a 33.50% discount, bringing the total cost to $399 per year [1].

Core Viewpoint - Dianthus Therapeutics Inc. (NASDAQ:DNTH) is identified as one of the most shorted biotech stocks with significant upside potential, as highlighted by recent price target increases from Guggenheim and Oppenheimer [1][3]. Group 1: Price Target Adjustments - Guggenheim raised its price target for Dianthus Therapeutics from $100 to $200, indicating an upside potential of nearly 207% [1]. - Oppenheimer increased its price target from $62 to $125 while maintaining an Outperform rating, noting a year-to-date share gain of 22% compared to a 5% rise in the XBI index [3]. Group 2: Sales Projections - Guggenheim projects global peak sales of approximately $2.8 billion from CIDP patients and around $2 billion from the gMG indication, following updates to its sales model [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing treatments for severe autoimmune and inflammatory diseases through highly selective monoclonal antibodies, particularly their lead candidate claseprubart [4].

Core Viewpoint - Dianthus Therapeutics is conducting a conference call to discuss its latest developments and financial performance, indicating a focus on investor engagement and transparency [1] Company Overview - The call is led by Marino Garcia, the CEO of Dianthus Therapeutics, highlighting the leadership's role in communicating with investors [1] Presentation Details - A slide presentation is available on the Investors section of the Dianthus Therapeutics website, suggesting the company is providing additional resources for stakeholders to understand its performance and strategy [1] Q&A Session - The conference call will include a Q&A session following the prepared remarks, indicating an opportunity for investors to engage directly with the company's leadership [1]

Core Viewpoint - Dianthus Therapeutics (NASDAQ:DNTH) is a biopharmaceutical company focused on treatments for autoimmune and inflammatory diseases, with a recent price target set at $145 indicating a potential upside of 79.28% from its current price of $80.88 [1][5] Company Performance - The stock has experienced a remarkable 13-fold increase over the past two years, driven by advancements in its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), significantly boosting investor interest [2][5] - Currently, DNTH is priced at $80.68, reflecting a 23.74% increase, or a rise of $15.48, with fluctuations between $78 and $84.86 today, indicating strong investor activity [3][5] - The company has a market capitalization of approximately $2.92 billion and a trading volume of about 2.9 million shares, with the lowest price over the past year being $13.37, showcasing significant growth [4]

Core Viewpoint - Dianthus Therapeutics, Inc. has initiated a public offering of $400 million in common stock, with an additional option for underwriters to purchase up to $60 million more, aimed at advancing its clinical and preclinical development activities [1][2]. Group 1: Offering Details - The public offering consists of $400 million in shares of common stock or pre-funded warrants for certain investors [1]. - Underwriters will have a 30-day option to purchase an additional $60 million of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Company Background - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].

Core Viewpoint - Dianthus Therapeutics' stock experienced a significant increase following the announcement of advancing its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [1] Group 1 - The company is progressing with its CIDP treatment, which has positively impacted its stock performance [1]